Aimmune wins approval for peanut immunotherapy, charges 10k+
The FDA has approved the first treatment for peanut allergy, although it comes with some controversy.
Unlike most of the controversial drugs that come before the FDA, the bulk of questions don’t center around this drug’s effectiveness or side effects.
Palforzia, developed by Aimmune, has been shown to prevent the most severe reactions from exposure to small amounts of peanuts. In a Phase III trial, children given escalating doses of the drug were then given 600 mg peanut protein — about 2 peanuts — had a 67% chance of avoiding a severe reaction. For the placebo patients, the figure was 4%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.